Author Guidelines

Sections

1. Submission
2. Peer Review Process
3. Article Types
4. After Acceptance

1. Submission

Electronic submission of manuscripts

New submissions should be made via the Research Exchange submission portal https://wiley.atyponrex.com/journal/CEA

Should your manuscript proceed to the revision stage, you will be directed to make your revisions via the same submission portal. You may check the status of your submission at anytime by logging on to submission.wiley.com and clicking the “My Submissions” button. For technical help with the submission system, please review our FAQs or contact [email protected].

For help with submissions, please contact: [email protected].

If your paper requires an embargo, please notify [email protected] at point of submission. Embargos are subject to the approval of the Editorial Office.

For information about Preprints, Open Access and Data Sharing please see the Appendix

Article Preparation Support

Wiley Editing Services offers expert help with English Language Editing, as well as translation, manuscript formatting, figure illustration, figure formatting, and graphical abstract design – so you can submit your manuscript with confidence.

Also, check out our resources for Preparing Your Article for general guidance about writing and preparing your manuscript.

Submitting your article as a Clinical & Experimental Allergy ‘Free Format’ submission manuscript

Clinical & Experimental Allergy now offers Free Format submission for a simplified and streamlined submission process.

Before you submit, you will need:

  • Your manuscript: this should be an editable file including text, figures, and tables, or separate files — whichever you prefer. All required sections should be contained in your manuscript, including abstract, introduction, methods, results, and conclusions. Figures and tables should have legends. Figures should be uploaded in high resolution so that the editors and reviewers can assess them. If the figures are not of sufficiently high quality to interpret, processing of your manuscript may be delayed. References may be submitted in any style or format, as long as it is consistent throughout the manuscript. Supporting information should be submitted in a separate file. Your manuscript may be sent back to you for revision if the text or illustrations are difficult to read or the quality of English language is poor.
  • An ORCID ID, freely available at https://orcid.org.
  • The title page of the manuscript, including:
    • Your co-author details, including affiliation.
    • Statement of contribution for authors, listing each author’s contribution to the manuscript.
  • If your article includes original research: An ethical statement which should include any necessary ethical approval(s) and consent procedures.
    • The date, approval number/code and name of the approving ethics committee and any clinical trial or systematic review registration information (number and database) should be included.
    • Human studies: A statement confirming receipt of informed, written consent from patients.
    • Animal studies: A statement confirming approval of procedures by appropriate regulatory body.

If you are invited to revise your manuscript after peer review, the journal will request the revised manuscript to be formatted according to journal requirements as described below.

Submitting your article or revised article as a ‘Formatted for Clinical & Experimental Allergy manuscript’

Main Text File

Manuscripts can be uploaded either as a single document (containing the main text, tables and figures), or with figures and tables provided as separate files. Should your manuscript reach revision stage, figures and tables must be provided as separate files. The main manuscript file can be submitted in Microsoft Word (.doc or .docx) or LaTex (.tex) format.

If submitting your manuscript file in LaTex format via Research Exchange, select the file designation “Main Document – LaTeX .tex File” on upload. When submitting a Latex Main Document, you must also provide a PDF version of the manuscript for Peer Review. Please upload this file as “Main Document - LaTeX PDF.” All supporting files that are referred to in the Latex Main Document should be uploaded as a “LaTeX Supplementary File.”

Your main document file should include:

  • A short informative title containing the major key words. The title should not contain abbreviations. The title should be succinct, with less than 120 characters including spaces.
  • The full names of the authors with institutional affiliations where the work was conducted, with a footnote for the author’s present address if different from where the work was conducted;
  • Acknowledgments;
  • Abstract structured (intro/methods/results/conclusion) or unstructured, according to the requirements of the article type (see below). Maximum word count for all abstracts is 300 words.
  • Up to seven keywords;
  • Key Messages. Authors of original articles, review articles, clinical trials, diagnostic test accuracy studies and Cochrane Corners will need to provide 3 ‘key messages’, written with a clinical or general audience in mind, which summarise the key findings of their paper. Each key message is a maximum of 15 words, and the messages should be bulleted. Key messages are published as a box within the article – usually on the second page of the pdf – and should clearly summarise the key findings. Only standard abbreviations can be used in key messages.
  • Main body: formatted as introduction, methods, results, discussion, conclusion
  • References;
  • Tables (each table complete with title and footnotes);
  • Figures: Figure legends must be added beneath each individual image during upload AND as a complete list in the text.

Reference Style

This journal uses Vancouver reference style. Review the reference style guidelines prior to submission. 

Figures and Supporting Information

Figures and supporting information should be supplied as separate files. You should review the basic figure requirements for manuscripts for peer review, as well as the more detailed post-acceptance figure requirements. Figures are accepted for publication in vector format but cannot be published in raster file format. View Wiley’s FAQs on supporting information.

Graphical TOC/Abstract

Authors will be invited to submit a graphical abstract for presentation in the journal table of contents and use in social media dissemination of the article. Graphical abstracts should be submitted for all original and review articles, but are not needed for research letters. Editorials should have an accompanying graphic/image.

For these article types we require that the Author supply:

  1. An image: either one of the article images, or a separate image which conforms to standard image supply rules regarding resolution and fits within the dimensions of 50mm x 60mm and is fully legible at this size.
  2. Short abstract text: no more than 80 words of text summarizing the key findings presented in the paper.

Please follow the guidelines for Graphical abstract.

Video Abstracts

Authors are encouraged to include a video abstract to help with dissemination of their published article. These are included as an ‘Author Insights’ link – see this article for an example https://onlinelibrary.wiley.com/doi/full/10.1111/cea.14180.  

Examples of Clinical and Experimental Allergy video abstracts are here:

Video abstracts should be a maximum of 10 slides and 90 seconds. The first slide should include the Clinical and Experimental Allergy logo, the date of the publication, the title and author list of the publication. Once a video abstract has been created, please send the link to our editorial office [email protected] and we will review the video abstract prior to inclusion as an Author Insights link.

Guidelines on Publishing and Research Ethics in Journal Articles

The journal requires that you include in the manuscript details IRB approvals, ethical treatment of human and animal research participants, and gathering of informed consent, as appropriate. Please review Wiley’s policies surrounding human studies, animal studies, clinical trial registration, biosecurity, and research reporting guidelines.
This journal follows the core practices of the Committee on Publication Ethics (COPE) and handles cases of research and publication misconduct accordingly (https://publicationethics.org/core-practices).
This journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read Wiley’s Top 10 Publishing Ethics Tips for Authors and Wiley’s Publication Ethics Guidelines.
This journal requires that Authors adhere to the relevant EQUATOR guideline where appropriate and submit a checklist with their submission.

Immunity, Inflammation and Disease

Clinical & Experimental Allergy collaborates with Wiley’s open access journal Immunity, Inflammation and Disease, to enable rapid publication of good quality research that we are unable to accept for publication in Clinical & Experimental Allergy. Authors will be offered the option of having the paper, along with any related peer reviews, automatically transferred for consideration by the Editor of Immunity, Inflammation and Disease. Authors will not need to reformat or rewrite their manuscript at this stage, and publication decisions will be made a short time after the transfer takes place. The Editor of Immunity, Inflammation and Disease will accept submissions that report well-conducted research which reaches the standard acceptable for publication. Immunity, Inflammation and Disease is a Wiley Open Access journal and article publication fees apply. For more information please go to Immunity. Inflammation and Disease.

2. Peer Review Process

This journal operates under a single-blind peer review model. Papers will only be sent to review if the Editor-in-Chief determines that the paper meets the appropriate quality and relevance requirements.

You will need to include the contact details of three experts whom you recommend as peer reviewers, at the time of manuscript submission. If you wish to recommend others, or oppose potential peer reviewers, then you are able to do so. If your manuscript has already undergone peer review at another journal, please forward the previous peer reviews with your submission, as that is likely to shorten our decision time and reduce any unnecessary duplication of reviewer effort.

Wiley's policy on the confidentiality of the review process is available here.

3. Article Types

This journal requires that Authors adhere to the relevant EQUATOR guideline where appropriate and submit a checklist with their submission.

  • Description

    Reports of new research findings or conceptual analyses that make a significant contribution to knowledge. Suitable manuscripts include those dealing with: epidemiology, underlying mechanisms, diagnosis, treatment and prevention of allergic (and related) diseases. These might include the study of methods of controlling allergic reactions, human and animal models of hypersensitivity and other aspects of mechanistic and applied clinical allergy in its broadest sense including clinical trials.


    Content Limit

    3500 words

    8 figures or tables


    Abstract/Structure

    300 words

    Abstract Structure:

    - Background: what is the context and aim of the study?

    - Methods: what were the principal methods used?

    - Results: What are the most important findings?

    - Conclusions: What is the most important conclusion drawn, and what is the clinical or research relevance of the results?


    Other Requirements

    Data Availability Statement

    IRB Statement

    Three bulleted key messages summarising the findings of the manuscript, each message maximum 15 words’

  • Description

    Solicited and unsolicited review articles and opinion pieces on subjects of topical interest to experimental and clinical allergists.

    A review article is not the same as a systematic review.


    Content Limit

    4500 words

    Minimum 4 tables/figures including at least 2 figures and max 150 references


    Abstract/Structure

    An unstructured abstract is required, summarizing the key messages of the review article.

    Bulleted list of key messages of the review article.

    Three bulleted key messages summarising the findings of the manuscript, each message maximum 15 words

  • Description

    We strongly encourage the submission of systematic reviews and other forms of evidence synthesis. Systematic reviews should be registered (e.g., PROSPERO, or Open Science Framework) and should clearly describe the population, intervention or exposure of interest and the outcomes. We accept shortened co-publications of Cochrane Systematic Reviews which are relevant to the field of allergy. All systematic review submissions should be accompanied by the relevant checklist e.g., PRISMA


    Abstract/Structure

    Abstract Structure:

    - Objective: aim of the review.

    - Design: type of systematic review or meta-analysis, and methods for study appraisal (risk of bias assessment) and data synthesis.

    - Data sources: where included studies were identified from e.g., the databases searched.

    - Eligibility criteria for selecting studies: inclusion and exclusion criteria (specifying study design, participants, interventions and outcomes, as appropriate).

    - Results: main findings with 95% confidence intervals.

    - Conclusions: primary conclusions and their implications.

    - Systematic review registration: registry and number.

  • Description

    By invitation only.


    Content Limit

    1500 words

    9 references

    2 figures or tables


    Abstract/Structure

    No

  • Description

    These have no abstract and begin ‘To the Editor’. If your original article submission is not considered significant enough to merit publication as a full article, we may ask you to revise and reformat it as a research letter. The journal does not accept case reports.

    Supplementary information is not allowed on this article type. If authors wish to refer to more details of the methods used or additional results related to the work, they can upload any extra material to an open access repository such as Open Science Framework or Zenodo and include a link to this external material in the Research letter.


    Research Letters should include a ‘Summary box’ with two bulleted statements summarising the letter, each statement a maximum 15 words in length.


    Content Limit

    900 words

    9 references 

    1 table or multipanel figure (no more than four sub figures)

  • Description

    We encourage correspondence concerning recent publications in the journal. Correspondence letters must be submitted via https://mc.manuscriptcentral.com/cea. The authors of the original work will be invited to respond.

    Time limit for correspondence
    No more than 3 months after issue publication

    Content Limit

    1000 limit

    Abstract/Structure

    No

  • Description

    Clinical trials should be registered on a WHO compliant clinical trials registry (e.g. ISRCTN, clinicaltrials.gov) and should be reported according to CONSORT guidance and the submission should include a completed CONSORT checklist and a copy of the clinical trial protocol as supplementary material, dated prior to commencement of the trial.


    Abstract/Structure

    Abstract structure as per CONSORT guidance. The clinical trial registration number should be included in the abstract.

    Word limits and Table/Figure limits are the same as for Original Articles.

    Three bulleted key messages summarising the findings of the manuscript, each message maximum 15 words.

  • Description

    Please report diagnostic test accuracy studies in line with STARD guidance and include a STARD checklist with the submission.


    Abstract/Structure

    A structured abstract is required

    Word limits and Table/Figure limits are the same as for Original Articles.

    Three bulleted key messages summarising the findings of the manuscript, each message maximum 15 words.

  • Description - by invitation only

    Contact Parisut Kimkool [email protected] if you would like to contribute to our regular Cochrane Corner series. Cochrane Corners have a brief introductory paragraph (<150 words), followed by a disclaimer 'This is an abstract of a Cochrane review published in the Cochrane Database of Systematic Reviews 2021, Issue 3. (see www.cochranelibrary.com for information). Cochrane reviews are regularly updated as new evidence emerges and in response to feedback, and the Cochrane Library should be consulted for the most recent version of the review' then the relevant Cochrane Review Abstract reproduced in full, then a section titled 'commentary' (<500 words) which aims to put the Cochrane Review findings into a global clinical context, considering such issues as cost, acceptability and burden of treatment, which are not usually considered in Cochrane Reviews. Cochrane Corners can include 1 Table or Figure, which if appropriate can be taken from the Cochrane Review. There is no abstract, the maximum number of authors is 3, maximum word count is 1500 in total from introductory paragraph through to the end of the commentary, and maximum 9 references. There should be 3 key messages summarising the findings. See doi: 10.1111/cea.13904 for an example.

    Three bulleted key messages summarising the findings of the manuscript, each message maximum 15 words.

  • Description

    The Journal does not publish case reports; authors of case reports are encouraged to submit to Wiley’s journal, Clinical Case Reports.

  • Description

    Debate articles present two contrasting opinions on a topical or controversial area of allergy. The articles are divided into a ‘pro’ section and a ‘con’ section, each a maximum of 750 words


    Content Limit

    750 words with a key messages box containing a maximum of 3 statements, each one a maximum of 15 words
    2 figures or tables (usually 1 for the ‘pro’ section and 1 for the ‘con’ section)
    The reference limit for the whole pro-con article is 9
    Maximum of 6 authors - 3 for the ‘pro’ and 3 for the ‘con’ section


    Abstract/Structure

    No

  • Description

    Clinical Question articles are topical summaries of issues related to the clinical management of people with suspected or proven allergic conditions. They should be up to date, relevant and of interest to a clinical audience. The article has a primary educational objective and at least one author should be an expert in the specific clinical field which the article addresses.


    Content Limit

    1500 words
    9 references
    2 figures or tables
    No key messages required


    Abstract/Structure

    No

  • Description

    We encourage submission of guidelines, especially guidelines developed by national or international health agencies or professional bodies. Clinical practice guidelines should be reported in line with the AGREE recommendations and an AGREE reporting checklist should be included as supplementary material. Clinical practice guidelines should include statements in the methods section about how the guideline topic was prioritised and how patients, carers or the public were involved in guideline development.

    Clinical Practice Guidelines may be submitted as either a full-length article or as a brief summary in Research Letter format, with a link to the full guideline on an external site. These instructions are for manuscripts submitted as full-length articles.


    Content Limit

    4500 words
    150 references
    10 figures or tables
    No key messages required


    Abstract/Structure

    This should be a maximum of 300 words, and can be structured or unstructured according to the topic and methodology of the Clinical Practice Guideline.


    Executive summary

    Optional bulleted list of key recommendations, after the abstract but before the main guideline text – maximum 500 words


4. After Acceptance

First Look

After your paper is accepted, your files will be assessed by the editorial office to ensure they are ready for production. You may be contacted if any updates or final files are required. Otherwise, your paper will be sent to the production team. 

Wiley Author Services

When an accepted article is received by Wiley’s production team, the corresponding author will receive an email asking them to login or register with Wiley Author Services. You will be asked to sign a publication license at this point as well as pay for any applicable APCs (Article Publication Charges) for Open Access papers.

Copyright & Licensing

You may choose to publish under the terms of the journal’s standard copyright agreement, or Open Access under the terms of a Creative Commons License.
Standard re-use and licensing rights vary by journal. Note that certain funders mandate a particular type of CC license be used. This journal uses the CC-BY/CC-BY-NC/CC-BY-NC-ND Creative Commons License.
Self-Archiving Definitions and Policies: Note that the journal’s standard copyright agreement allows for self-archiving of different versions of the article under specific conditions.

 Accepted Articles

The journal offers Wiley’s Accepted Articles service for all manuscripts. Manuscripts accepted ‘in press’ are published online shortly after acceptance, prior to copy-editing or typesetting and appear in PDF format only. After the final, post-proof version article is published (the article of record), the DOI remains valid and can still be used to cite and access the post-proof article.

Accepted Articles will be indexed by PubMed; submitting authors should carefully check the names and affiliations of all authors provided in the cover page of the manuscript so it is accurate for indexing. The final copyedited and proofed articles will appear in an issue on Wiley Online Library; the link to the article in PubMed will update automatically.

Proofs

Authors will receive an e-mail notification with a link and instructions for accessing HTML page proofs online/with their proofs included as a pdf. Authors should also make sure that any renumbered tables, figures, or references match text citations and that figure legends correspond with text citations and actual figures. Proofs must be returned within 48 hours of receipt of the email.

Early View

The journal offers rapid publication of the post-proof article via Wiley’s Early View service. Early View (Online Version of Record) articles are published on Wiley Online Library before inclusion in an issue but after the proofs have been checked and returned. Note there may be a delay after corrections are received before your article appears online, as Editors also need to review proofs. Once your article is published on Early View no further changes to your article are possible. Your Early View article is fully citable and carries an online publication date and DOI for citations.

Article Promotion Support

Wiley Editing Services offers professional video, design, and writing services to create shareable video abstracts, infographics, conference posters, lay summaries, and research news stories for your research – so you can help your research get the attention it deserves.

 Access and Sharing

When your article is published online:

  • You receive an email alert (if requested).
  • You can share your published article through social media.
  • As the author, you retain free access (after accepting the Terms & Conditions of use, you can view your article).
  • The corresponding author and co-authors can nominate up to ten colleagues to receive a publication alert and free online access to your article.

You can now order print copies of your article (instructions are sent at proofing stage or use the link, www.sheridan.com/wiley/eoc). 

Find out how to promote your work here.

Measuring the impact of your work

Wiley also helps you measure the impact of your research through our specialist partnership with Altmetric.

Author Name Change Policy

In cases where authors wish to change their name following publication, Wiley will update and republish the paper and redeliver the updated metadata to indexing services. Our editorial and production teams will use discretion in recognizing that name changes may be of a sensitive and private nature for various reasons including (but not limited to) alignment with gender identity, or as a result of marriage, divorce, or religious conversion. Accordingly, to protect the author’s privacy, we will not publish a correction notice to the paper, and we will not notify co-authors of the change. Authors should contact the journal’s Editorial Office, [email protected], with their name change request.

Appendix

Open Access

Preprint policy:

Please find the Wiley preprint policy here.

This journal accepts articles previously published on preprint servers.

This journal will consider for review articles previously available as preprints on non-commercial servers such as ArXiv, bioRxiv, psyArXiv, SocArXiv, engrXiv, etc. You may also post the submitted version of a manuscript to a preprint server at any time. You are requested to update any pre-publication versions with a link to the final published article.

Data Sharing and Data Availability

This journal expects data sharing. Review Wiley’s Data Sharing policy where you will be able to see and select the data availability statement that is right for your submission.

Data Citation

Please review Wiley’s Data Citation policy.

Data Protection

By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication. Please review Wiley’s Data Protection Policy to learn more.

Funding

You should list all funding sources in the Acknowledgments section. You are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature.

 Authorship

All listed authors should have contributed to the manuscript substantially and have agreed to the final submitted version. Review editorial standards and scroll down for a description of authorship criteria.

ORCID

This journal requires the submitting author to provide an ORCID ID. Please refer to Wiley’s resources on ORCID.

 Reproduction of Copyright Material

If excerpts from copyrighted works owned by third parties are included, credit must be shown in the contribution. It is your responsibility to also obtain written permission for reproduction from the copyright owners. For more information visit Wiley’s Copyright Terms & Conditions FAQ.

The corresponding author is responsible for obtaining written permission to reproduce the material "in print and other media" from the publisher of the original source, and for supplying Wiley with that permission upon submission.

 Resource Identification Initiative

The journal supports the Resource Identification Initiative, which aims to promote research resource identification, discovery, and reuse. This initiative, led by the Neuroscience Information Framework and the Oregon Health & Science University Library, provides unique identifiers for antibodies, model organisms, cell lines, and tools including software and databases. These IDs, called Research Resource Identifiers (RRIDs), are machine-readable and can be used to search for all papers where a particular resource was used and to increase access to critical data to help researchers identify suitable reagents and tools.

You will be asked to use RRIDs to cite the resources used in your research where applicable in the text, similar to a regular citation or Genbank Accession number. For antibodies, you should include in the citation the vendor, catalogue number, and RRID both in the text upon first mention in the Methods section. For software tools and databases, please provide the name of the resource followed by the resource website, if available, and the RRID. For model organisms, the RRID alone is sufficient.

Additionally, you must include the RRIDs in the list of keywords associated with the manuscript.

 To Obtain Research Resource Identifiers (RRIDs):

  1. Use the Resource Identification Portal, created by the Resource Identification Initiative Working Group.
  2. Search for the research resource (please see the section titled “Search Features and Tips” for more information).
  3. Click on the “Cite This” button to obtain the citation and insert the citation into the manuscript text.

If there is a resource that is not found within the Resource Identification Portal, you are asked to register the resource with the appropriate resource authority. Information on how to do this is provided in the “Resource Citation Guidelines” section of the Portal.

If any difficulties in obtaining identifiers arise, please contact [email protected] for assistance.

Example Citations:

Antibodies: "Wnt3 was localized using a rabbit polyclonal antibody C64F2 against Wnt3 (Cell Signaling Technology, Cat# 2721S, RRID: AB_2215411)"
Model Organisms: "Experiments were conducted in c. elegans strain SP304 (RRID:CGC_SP304)"
Cell lines: "Experiments were conducted in PC12 CLS cells (CLS Cat# 500311/p701_PC-12, RRID:CVCL_0481)"
Tools, Software, and Databases: "Image analysis was conducted with CellProfiler Image Analysis Software, V2.0 (http://www.cellprofiler.org, RRID:nif-0000-00280)"

Species Names

Upon its first use in the title, abstract, and text, the common name of a species should be followed by the scientific name (genus, species, and authority) in parentheses. For well-known species, however, scientific names may be omitted from article titles. If no common name exists in English, only the scientific name should be used.

Genetic Nomenclature

Sequence variants should be described in the text and tables using both DNA and protein designations whenever appropriate. Sequence variant nomenclature must follow the current HGVS guidelines; see varnomen.hgvs.org, where examples of acceptable nomenclature are provided.

 Sequence Data

Nucleotide sequence data can be submitted in electronic form to any of the three major collaborative databases: DDBJ, EMBL, or GenBank. It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL, and GenBank on a daily basis. The suggested wording for referring to accession-number information is: ‘These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number U12345’. Addresses are as follows:

Proteins sequence data should be submitted to either of the following repositories:

Structural Data

For papers describing structural data, atomic coordinates and the associated experimental data should be deposited in the appropriate databank (see below). Please note that the data in databanks must be released, at the latest, upon publication of the article. We trust in the cooperation of our authors to ensure that atomic coordinates and experimental data are released on time.

  • Organic and organometallic compounds:  Crystallographic data should not be sent as Supporting Information, but should be deposited with the Cambridge Crystallographic Data Centre (CCDC) at cam.ac.uk/services/structure%5Fdeposit.
  • Inorganic compounds: Fachinformationszentrum Karlsruhe (FIZ; fiz-karlsruhe.de).
  • Proteins and nucleic acids: Protein Data Bank (org/pdb).
  • NMR spectroscopy data: BioMagResBank (wisc.edu).

_______________________________________

Author Guidelines updated February 2021